DK0918545T3 - Tumorbehandling - Google Patents

Tumorbehandling

Info

Publication number
DK0918545T3
DK0918545T3 DK97945975T DK97945975T DK0918545T3 DK 0918545 T3 DK0918545 T3 DK 0918545T3 DK 97945975 T DK97945975 T DK 97945975T DK 97945975 T DK97945975 T DK 97945975T DK 0918545 T3 DK0918545 T3 DK 0918545T3
Authority
DK
Denmark
Prior art keywords
compound
vascular compartment
tumor treatment
mammal
following administration
Prior art date
Application number
DK97945975T
Other languages
Danish (da)
English (en)
Inventor
Kenneth Dawson Bagshawe
Original Assignee
Enzacta R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzacta R & D Ltd filed Critical Enzacta R & D Ltd
Application granted granted Critical
Publication of DK0918545T3 publication Critical patent/DK0918545T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK97945975T 1996-11-30 1997-11-28 Tumorbehandling DK0918545T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624993.3A GB9624993D0 (en) 1996-11-30 1996-11-30 Tumour therapy
PCT/GB1997/003284 WO1998024478A2 (en) 1996-11-30 1997-11-28 Tumour therapy

Publications (1)

Publication Number Publication Date
DK0918545T3 true DK0918545T3 (da) 2000-11-27

Family

ID=10803777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97945975T DK0918545T3 (da) 1996-11-30 1997-11-28 Tumorbehandling

Country Status (11)

Country Link
EP (1) EP0918545B1 (ja)
JP (1) JP2001505220A (ja)
AT (1) ATE194499T1 (ja)
CA (1) CA2273218A1 (ja)
DE (1) DE69702527T2 (ja)
DK (1) DK0918545T3 (ja)
ES (1) ES2150286T3 (ja)
GB (1) GB9624993D0 (ja)
GR (1) GR3034592T3 (ja)
PT (1) PT918545E (ja)
WO (1) WO1998024478A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9812550D0 (en) * 1998-06-11 1998-08-05 Aepact Ltd Tumour therapy and imaging
JP2005517674A (ja) * 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
CA3003482A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
JP2000502698A (ja) * 1995-12-29 2000-03-07 エンザクタ アール アンド ディ リミテッド 細胞毒性試薬

Also Published As

Publication number Publication date
WO1998024478A2 (en) 1998-06-11
PT918545E (pt) 2000-12-29
DE69702527T2 (de) 2001-03-08
ES2150286T3 (es) 2000-11-16
GB9624993D0 (en) 1997-01-15
GR3034592T3 (en) 2001-01-31
JP2001505220A (ja) 2001-04-17
EP0918545B1 (en) 2000-07-12
ATE194499T1 (de) 2000-07-15
WO1998024478A3 (en) 1998-07-30
DE69702527D1 (de) 2000-08-17
CA2273218A1 (en) 1998-06-11
EP0918545A2 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
NO996120L (no) Imidazolyl-cykliske acetaler
MY122383A (en) Cyclic boroproline compounds
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
AU527371B2 (en) Amidine
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
NZ334691A (en) Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
NO20014415L (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DK0918545T3 (da) Tumorbehandling
DE69427706T2 (de) Cryptophycine
NO974275L (no) Fremgangsmåte for behandling av tumorer
FI904521A0 (fi) Komposition foer inducering av sammanbindning.
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
WO2003105774A3 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS THEREOF
TR200501763T2 (tr) Tedavi ve ilaç tarama yöntemleri
EP0664281A4 (ja)
DE59712247D1 (de) Mammakarzinom-assoziiertes gen
WO1996007421A3 (en) An antiulcer medicine comprising a protein possessing all growth factor activity and a proton pump inhibitor
RU99122488A (ru) Способ лечения рака эндометрия
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof